Impact of Gleason pattern up gradation after radical prostatectomy for carcinoma prostate patients with low biopsy score (≤ 6)

Kulkarni, Jagdeesh N.; Valsangkar, Rohan; Jadhav, Yogesh; Singh, Dayal Partap

doi:10.4103/0973-1482.92021

Cited by 8 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Gleason score is the most widely used predictive preoperative histological parameter of tumor spread in urological practice and is considered capable of predicting tumor behavior, with the ability to differentiate between aggressive and benign disease (24,25). However, previous studies (27-29) and our ongoing study indicate that the Gleason score is likely underestimated by preoperative biopsy of the prostate in approximately 40% of cases, resulting in false-negative results. This may hinder the accurate diagnosis of benign vs aggressive prostate cancer (27-29).…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

Cyclin D1 expression in prostate carcinoma

Pereira

Ravinal

Costa

et al. 2014

Braz J Med Biol Res

View full text Add to dashboard Cite

The purpose of this study was to investigate the relationship between cyclin D1 expression and clinicopathological parameters in patients with prostate carcinoma. We assessed cyclin D1 expression by conventional immunohistochemistry in 85 patients who underwent radical prostatectomy for prostate carcinoma and 10 normal prostate tissue samples retrieved from autopsies. We measured nuclear immunostaining in the entire tumor area and based the results on the percentage of positive tumor cells. The preoperative prostate-specific antigen (PSA) level was 8.68±5.16 ng/mL (mean±SD). Cyclin D1 staining was positive (cyclin D1 expression in >5% of tumor cells) in 64 cases (75.4%) and negative (cyclin D1 expression in ≤5% of tumor cells) in 21 cases (including 15 cases with no immunostaining). Normal prostate tissues were negative for cyclin D1. Among patients with a high-grade Gleason score (≥7), 86% of patients demonstrated cyclin D1 immunostaining of >5% (P<0.05). In the crude analysis of cyclin D1 expression, the high-grade Gleason score group showed a mean expression of 39.6%, compared to 26.9% in the low-grade Gleason score group (P<0.05). Perineural invasion tended to be associated with cyclin D1 expression (P=0.07), whereas cyclin D1 expression was not associated with PSA levels or other parameters. Our results suggest that high cyclin D1 expression could be a potential marker for tumor aggressiveness.

show abstract

Section: Discussionmentioning

confidence: 70%

“…However, previous studies (27-29) and our ongoing study indicate that the Gleason score is likely underestimated by preoperative biopsy of the prostate in approximately 40% of cases, resulting in false-negative results. This may hinder the accurate diagnosis of benign vs aggressive prostate cancer (27-29). …”

Section: Discussionmentioning

confidence: 70%

Cyclin D1 expression in prostate carcinoma

Pereira

Ravinal

Costa

et al. 2014

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…After reviewing several series, it appears that Epstein's criteria for very low risk disease are useful in predicting organ confined disease in about 90% of the cases, but Gleason score reclassification happens in 25-35% of the cases after pathological assessment [21,22], and positive margins occurs in 7-12% of the cases. Although this would seem to worsen the prognosis, there is no evidence that these findings are necessarily associated with disease progression and the need for additional treatment, therefore we consider that meeting Epstein' criteria allows predicting a favorable outcome.…”

Section: Discussionmentioning

confidence: 99%

Histological Findings in Very Low Risk Prostate Cancer Patients Managed with Radical Prostatectomy

et al. 2017

View full text Add to dashboard Cite

AbstractObjectives: To describe the histological findings in patients with prostate cancer (PCa) clinically classified as very low risk who underwent treatment with radical prostatectomy (RP). Material and methods: A retrospective observational study was conducted. Clinical records of patients who underwent RP between 2007-2015 who met Epstein criteria for very low risk disease were reviewed. Histological diagnosis was described and analyzed to determine if such criteria predicted very low risk. Results: A total of 609 records were reviewed; 83 (13.6%) met Epstein’s criteria. Mean age was 59 (SD±7) years and median PSA at diagnosis was 5.4 ng/dl (IQR 4.3 – 6.8). Pathology showed a median tumor volume of 4% (IQR 1 – 10%). Gleason score was 3+3 in 55 (66.3%) cases, but 28 (33.7%) were reclassified to a greater score. Two (2.4%) patients were reclassified as pT3a, 80 (96.4%) as pT2 and 1 (1.2%) was found to be pT0. In those subjected to pelvic lymphadenectomy (42.2%) no positive lymph nodes were found. Conclusions: Up to one-third of the patients clinically classified with very low risk PCa had a greater Gleason score. Only 3% had locally advanced tumors, which is comparable to previous studies. Epstein’s criteria seem to be adequate in predicting organ-confined disease.

show abstract

“…Espécimes provenientes de BaG apresentam um escore de Gleason comumente menor com relação à prostatectomia radical. Estima-se que mais de 50% apresentem um escore menor em relação à PR (COOKSON;FLESHNER et al, 1997;CRAWFORD et al, 2000;KULKARNI;VALSANGKAR et al, 2011). Outros estudos demonstraram que cerca de 40% dos homens diagnosticados com tumores de baixo grau por BaG terão como diagnóstico final tumores de alto grau (BOSTWICK, 1994;GREGORI;VIEWEG et al, 2001;CAM;YUCEL et al, 2002).…”

Section: Discussionunclassified

Expressão de ciclina D1 em adenocarcinoma de próstata utilizando a técnica de imunohistoquímica

Pereira¹

View full text Add to dashboard Cite

Impact of Gleason pattern up gradation after radical prostatectomy for carcinoma prostate patients with low biopsy score (≤ 6)

Cited by 8 publications

References 27 publications

Cyclin D1 expression in prostate carcinoma

Cyclin D1 expression in prostate carcinoma

Histological Findings in Very Low Risk Prostate Cancer Patients Managed with Radical Prostatectomy

Expressão de ciclina D1 em adenocarcinoma de próstata utilizando a técnica de imunohistoquímica

Contact Info

Product

Resources

About